Earnings

Braveheart Bio Q2 EPS $(2.51)

Sep 8, 2026 · 04:37 PM ET· updated 2h ago

Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of $(0.14) per share

Why It Matters

Braveheart Bio lost much more money per share than experts thought it would, and the loss got way bigger than last quarter. When a company's losses grow fast like this, it's worth watching to see if they're spending money on important research or if something went wrong.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BRVE30.38

+3.64 (+13.59%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.